AbbVie's Skyrizi And Rinvoq Deserve The Premium Growth Valuation

Group 1 - The article emphasizes the importance of conducting personal in-depth research before making investment decisions due to the inherent risks involved [2] - It highlights that past performance is not indicative of future results, suggesting caution for investors [2] - The analysis is presented as informational and does not constitute professional investment advice, indicating that readers should consider their own financial situations [2] Group 2 - The article mentions that the analysts contributing to the platform may not be licensed or certified, which could affect the reliability of the information provided [2] - It clarifies that there are no existing stock or derivative positions in the companies mentioned, which may suggest an unbiased perspective [1] - The disclosure indicates that the opinions expressed are personal and not influenced by any business relationships with the companies discussed [1]